Clinical Study
Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus
Table 1
Baseline characteristics of the participants in each group.
| | Placebo | Theracurmin® | value |
| | Sex (M/F) | 13/4 | 9/6 | 0.450 | | Age (years) | | | 0.857 | | Antihypertensive drug (% of total) | 88.2 | 86.7 | >0.999 | | α-Glucosidase inhibitor (% of total) | 23.5 | 13.3 | 0.658 | | DPP-4inhibitor (% of total) | 11.8 | 13.3 | >0.999 | | Sulfonylurea (% of total) | 0 | 13.3 | 0.212 | | Biguanide (% of total) | 23.5 | 13.3 | 0.659 | | Glinide (% of total) | 0 | 6.7 | 0.469 | | Thiazolidinediones (% of total) | 5.9 | 0 | >0.999 | | BMI (kg/m2) | | | 0.951 | | SBP (mmHg) | | | 0.474 | | DBP (mmHg) | | | 0.901 | | HbA1c (%) | 6.1 [6.0, 6.7] | 6.1 [6.0, 6.3] | 0.775 | | BS (mg/dL) | 110.0 [99.5, 160.5] | 109.5 [100.0, 145.8] | 0.766 | | TG (mg/dL) | 159 [88, 197] | 144 [86, 177] | 0.521 | | LDL-C (mg/dL) | | | 0.860 | | HDL-C (mg/dL) | | | 0.063 | | UA (mg/dL) | | | 0.366 | | γ-GTP (IU/L) | 29.0 [21.5, 49.5] | 32.0 [21.0, 57.0] | 0.910 | | Cre (mg/dL) | 0.8 [0.8, 0.9] | 0.8 [0.6, 0.9] | 0.265 | | SAA-LDL (μg/mL) | 5.0 [4.8, 8.0] | 5.0 [4.0, 7.0] | 0.686 | | AT-LDL (μg/mL) | 1.3 [1.0, 1.4] | 1.1 [1.0, 1.3] | 0.823 | | Adiponectin (μg/mL) | | | 0.528 | | Leptin (ng/mL) | 5.1 [2.3, 7.0] | 4.7 [2.1, 15.4] | 0.865 | | hs-CRP (mg/dL) | 0.6 [0.4, 1.8] | 0.6 [0.2, 1.1] | 0.560 | | CCr (mL/min/1.73m2) | | | 0.857 |
|
|
Data are presented as the , or median [minimum, maximum], or number of patients. M/F: male/female; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: hemoglobin A1c; BS: blood sugar; TG: triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; UA: uric acid; γ-GTP: γ-glutamyl transpeptidase; Cre: creatinine; SAA-LDL: serum amyloid A-LDL; AT-LDL: a1-antitrypsin-LDL; hs-CRP: high-sensitivity C-reactive protein; CCr: creatinine clearance. |
